Clinical Trial Update: Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of recombinant human G-CSF for chemotherapy-induced neutropenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• Filgrastim (filgrastim)

Snippet

Sponsor: Shantha Biotechnics Limited | Conditions: Chemotherapy-Induced Neutropenia | Phase 3 | Status: COMPLETED